HIV Accelerated Liver Disease in Uganda
- Liver disease is a leading cause of death in people who have the human immunodeficiency virus (HIV). It especially affects those who have both HIV and hepatitis B or C viruses. Most research on HIV-related liver disease has been conducted in North America and Europe. However, HIV-related liver disease in Uganda and other African nations may involve other diseases that are not common in the West, and may not involve hepatitis B or C. Researchers want to study HIV-related liver disease in Uganda to learn more about the differences between Western and African trends of this disease.
- To study HIV-related liver disease in rural Uganda.
- Individuals at least 18 years of age who were tested for possible liver disease. Some participants will have HIV infection; others will be uninfected.
- All participants will be from rural areas of Uganda.
- Participants will have at least two study visits.
- Participants will have a physical exam and medical history. They will complete a questionnaire about health and quality of life. Blood, urine, and stool samples will be collected. Participants will also have a liver scan to check for liver scarring, and an ultrasound to take images of the liver.
- Participants who may have liver disease will visit a local hospital for more tests. A liver biopsy will be performed to collect liver tissue samples.
|Official Title:||HIV-Accelerated Liver Disease in Uganda|
|Study Start Date:||December 2011|
With improved survival following the introduction of highly active antiretroviral therapy (HAART), liver disease has become a leading cause of death among HIV-infected persons in Western cohorts, primarily affecting those co-infected with hepatitis B or C viruses (HBV, HCV). However, data are sparse on liver disease in HIV-infected populations from Uganda and other African nations, where the etiologies of liver disease are broader and include aflatoxin, schistosomiasis and other infectious and environmental agents. Our previous noninvasive study in rural, Rakai, Uganda indicates that the prevalence of significant liver fibrosis is high among HIV-infected individuals (17%) and is 50% higher than in HIV-uninfected persons, although the prevalence of viral hepatitis B co-infection is low (5%). The study presented here is a biopsy-based study that follows up on these results with the objectives of defining the etiology of liver disease and describing the mechanisms of HIV-accelerated liver fibrosis in this setting.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01524562
|Contact: Steven J Reynolds, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Steven J Reynolds, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|